Biosimilaires et facteurs médico-économiques

Borget, Isabelle; Grivel, T.

doi:10.1684/bdc.2010.1093

Search citation statements

Order By: Relevance

Paper Sections

Select...

What Savings Can Be Attributed To the Introduction Of Biosim1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2013

2018

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, there is a lack of independent analyses of the current and future savings from the use of biosimilars. Several authors reported estimates from the EGA where savings could attain up to €1.6 billion conditional on a 20 % price reduction for five patent-expired biologicals [3, 5, 8, 22]. This rough estimate does not provide information based on the currently available biosimilars but ratter based on expectation of their apparition.…”

Section: What Savings Can Be Attributed To the Introduction Of Biosimmentioning

confidence: 99%